GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GH Research reported that the FDA has confirmed its CMC and device plans appear Phase 3 ready, clearing the path for the pivotal program of GH001 in treatment-resistant depression. The company strengthened its balance sheet with $117.5 million in gross offering proceeds during Q2, ending the quarter with $362.7 million in cash and marketable securities.
Key figures
- Net loss
- $15.1 million
- Ga expenses
- $7.1 million
- Rd expenses
- $12.4 million
- Cash position
- $362.7 million
- Offering proceeds
- $117.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.